Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Profound Medical Corp. PROF
$13.76
+$0.05 (0.33%)
На 18:02, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
280421130.00000000
-
week52high
13.82
-
week52low
3.10
-
Revenue
6681000
-
P/E TTM
-10
-
Beta
1.25897100
-
EPS
-1.50000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 20:00
Описание компании
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Cowen & Co. | Outperform | Outperform | 07 мар 2022 г. |
| Raymond James | Outperform | Strong Buy | 22 февр 2022 г. |
| Jefferies | Buy | 15 сент 2020 г. | |
| Lake Street | Buy | 10 сент 2020 г. | |
| Cowen & Co. | Outperform | 01 апр 2020 г. | |
| Raymond James | Strong Buy | Outperform | 04 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Profound Medical: Upsides Leading Into FY22 Earnings, Revise To Buy
Seeking Alpha
04 февр 2023 г. в 06:13
Investors have repriced Profound Medical to the upside, with a strong rally that commenced in December. The momentum has continued into the new year, and we've re-entered with a small ticket.
Profound Medical (PROF) Surges 5.1%: Is This an Indication of Further Gains?
Zacks Investment Research
09 янв 2023 г. в 09:47
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Recent Price Trend in Profound Medical (PROF) is Your Friend, Here's Why
Zacks Investment Research
03 янв 2023 г. в 10:32
Profound Medical (PROF) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Profound Medical to Present at the 2022 Jefferies London Healthcare Conference
GlobeNewsWire
08 ноя 2022 г. в 16:30
TORONTO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that its CEO and Chairman, Arun Menawat, will present an update on the Company's business at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022 at 12:20 p.m. GMT.
Profound Medical Corp. (PROF) Q3 2022 Earnings Call Transcript
Seeking Alpha
05 ноя 2022 г. в 18:13
Profound Medical Corp. (NASDAQ:PROF ) Q3 2022 Results Conference Call November 3, 2022 4:30 PM ET Company Participants Stephen Kilmer - IR Dr. Arun Menawat - CEO Rashed Dewan - CFO Conference Call Participants Michael Sarcone - Jefferies Rahul Sarugaser - Raymond James Brian Gagnon - Gagnon Securities Operator Good day, and thank you for standing by. Welcome to the Profound Medical Incorporated Third Quarter 2022 Conference Call.